Y. Linkova

[Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety].

O. Boyko, A. Boyko, P. Yakovlev, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

V. Mazurov, O. Moiseeva, M. Gilyarov, 2021, Inflammation research : official journal of the European Histamine Research Society ... [et al.].

[The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis].

A. Boyko, K. Bakhtiyarova, N. Malkova, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

S. Fogt, A. Snegovoy, A. Zinkina-Orikhan, 2023, Safety and Risk of Pharmacotherapy.

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C

E. Klimova, O. Znoyko, R. Ivanov, 2013 .

[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].

O. Boyko, N. Totolyan, F. Khabirov, 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].

M. Morozova, E. Klimova, O. Znoyko, 2016, Terapevticheskii arkhiv.

Cepeginterferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C in patients co-infected with HIV-1 (final results of a multicenter randomized study)

V. Rassokhin, S. Romanova, F. Nagimova, 2016 .

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

V. Mazurov, A. Lila, M. Korolev, 2023, Rheumatology Science and Practice.